Abstract Short interfering RNAs (siRNAs) have proved to be a useful tool in studying gene function in plants, invertebrates and mammalian systems. Here we report the use of siRNAs for targeting the zebra¢sh dystrophin gene. This study demonstrates the e⁄cacy of siRNA-based gene silencing in this vertebrate model species, and illustrates the potential of this approach for determining the roles of multiple protein products expressed by a single gene during the early stages of development. In addition this study illustrates the usefulness of zebra¢sh as a model for muscle disease, and highlights the potential of siRNAbased gene targeting for disease analysis in this model organism.
Introduction
Gene silencing via double-stranded RNAs (dsRNAs) has had a signi¢cant impact on the ability to suppress gene expression in a wide range of species encompassing mice, human cells, plants, Drosophila melanogaster, Caenorhabditis elegans and yeast [1, 2] . To date, some studies of gene silencing in the zebra¢sh, which is an emerging model for disease analysis, have shown non-speci¢c e¡ects on gene expression following the microinjection of long ( s 30 bp) dsRNAs into embryos [3] . This outcome probably re£ects signi¢cant di¡erences in how vertebrates react to long dsRNA compared to invertebrates. To combat this problem, gene silencing approaches in mammalian systems are now based on using short interfering RNAs (siRNAs) to avoid generalised non-speci¢c e¡ects due to the induction of interferon and the activation of interferonresponse genes by long dsRNA [4] . Currently, the use of siRNAs for gene silencing in the zebra¢sh has not been documented, although a recent report has shown the e¡ectiveness of siRNA gene silencing in rainbow trout embryos [5] .
We decided to investigate the use of siRNAs in targeting the zebra¢sh Duchenne muscular dystrophy (dmd) gene. This approach was considered to o¡er potential in dissecting the roles of multiple proteins expressed by this gene. Importantly, the zebra¢sh o¡ers signi¢cant advantages compared to other model systems in the analysis of muscle-related diseases and early developmental e¡ects [6] .
In humans, the Duchenne muscular dystrophy gene contains eight promoters and expresses multiple transcripts with varying tissue speci¢city and developmental regulation [7, 8] . These transcripts, comprising alternatively spliced variants, encode proteins ranging in size from 427 kDa to 71 kDa (Fig. 1) . The full-length transcript expressed in muscle gives rise to a 427 kDa dystrophin protein (Dp427m) that links cytoskeletal actin to the extracellular matrix via the sarcolemmal dystrophinassociated glycoprotein complex (DGC) [8, 9] . The role of Dp427m ranges from muscle stabilisation during contraction to localisation of signalling molecules [10, 11] . The functional signi¢cance of those transcripts of the dystrophin gene encoding other 427 kDa proteins, and the smaller proteins ( Fig. 1 ) that are expressed in the retina and central nervous system during development, remains unclear [11] . Importantly, the zebra¢sh dmd gene expresses a number of isoforms that are similar in size to those found in human tissues [12] . In addition, zebra¢sh dystrophin (Dp427m) and the DGC are found in the sarcolemma with strong localisation to transverse myosepta [12^15] .
We describe here the use of siRNAs directed against the carboxy-terminal coding region of the zebra¢sh dystrophin gene to e¡ect restricted temporal targeting of the family of dystrophin gene transcripts. This study involved assessing the impact of siRNAs on the expression and localisation of dystrophin and selected members of the DGC, as well as muscle architecture, in order to determine the temporal window of e¡ect and speci¢city.
Materials and methods

siRNA design
Potential siRNA target sites in the zebra¢sh were determined using Oligoengine (DNA Engine), and Qiagen siRNA design (Qiagen) programmes. Synthesised siRNA duplexes were purchased from Xeragon in the case of the zebra¢sh dystrophin gene, and Dharmacon (Dallas, TX, USA) in the case of the siRNA against the green £uorescent protein (catalogue number D-001300-01-05; see Table 1 ). Stock concentrations of 50 WM were injected into single cell zebra¢sh embryos with an average injection volume of 0.3 nl.
Quantitative real-time polymerase chain reaction (PCR)
Zebra¢sh embryos were collected (10^20 embryos per time point), and RNA was extracted using Trizol (Invitrogen) and further puri¢ed using RNeasy columns (Qiagen). 1 Wg total RNA from each extraction was reverse transcribed using Superscript III (Invitrogen) and random primers in a 20 Wl reaction volume according to the manufacturer's instructions. cDNA samples were dye chemistries. All reactions (20 Wl) were performed in triplicate. Taqman universal mastermix (Applied Biosystems) was used with Taqman probes and a standard PCR mix using Platinum Taq DNA polymerase (Invitrogen) supplemented with 0.2 Wl/20 Wl reaction of a 1:2000 dilution of Sybr green dye (Molecular Probes) in the case of Sybr assays. All primers and probes were designed to conform to a universal cycling programme using the Primer Express programme (Applied Biosystems). Three control genes were used in all experiments (GAPDH, L-actin, 18S rRNA; the primers and probe for the latter were supplied by Applied Biosystems). The two least variable control genes were determined for each experiment and normalisation factors were calculated based on the geometric mean of these two genes using the program geNorm [16] . Relative expression was calculated using a modi¢ed comparative CT method with correction for di¡erent ampli¢cation e⁄ciencies [17] . See Table 1 for sequences of primers and probes.
Light microscopy
Images of zebra¢sh embryos were recorded using di¡erential interference contrast (DIC) optics on a Zeiss Axiovert S100 microscope and a Zeiss Axiocam digital camera.
Wholemount immunohistochemistry
Embryos were manually dechorionated and ¢xed in methanol overnight at 320 ‡C then washed in phosphate-bu¡ered saline (PBS), incubated 10 min in 1UPBS with 0.1% Triton X-100, washed in PTWs (1UPBS, 0.1% Tween 20, 0.3% saponin) and blocked for at least 1 h in PBTs (1UPBS; 1% bovine serum albumin, 0.1% Tween 20, 0.3% saponin). Following blocking, embryos were incubated with monoclonal antibodies against: dystrophin (MANCHO 12) (http://www.newi.ac.uk/morrisge/mabs.htm#DMD), L-sarcoglycan (NCL-b-SARC) and L-dystroglycan (NCL-b-DG) (Novocastra Laboratories, http:// www.novocastra.co.uk/md.htm), at 1:3 dilution in PBTs for at least 3 h at room temperature. The primary antibody was removed, then samples were washed six times in PTWs and were again blocked for at least 1 h in PBTs before incubation with secondary antibody. The secondary antibody, goat anti-mouse IgG lissamine-rhodamine conjugate (Jackson ImmunoResearch, USA), was pre-adsorbed against a crude zebra¢sh protein extract in PBTs before use then diluted at 1:50 in PBTs and incubated with samples for at least 1 h at room temperature. Antibody was removed and samples were washed with six PTWs washes then resuspended in 90% glycerol/10% PBS and rocked gently for 2 h prior to mounting. The rhodamine label was detected by scanning confocal imaging of embryos mounted in 1% low melting point agarose using a Leica TCS SP2 laser scanning confocal microscope [15] .
Electron microscopy
Embryos were manually dechorionated and ¢xed overnight at 4 ‡C in 2% paraformaldehyde, 2% glutaraldehyde in 0.1 M sodium cacodylate bu¡er pH 7.2 (SCB). After three washes in 1USCB samples were post¢xed in 1% osmium tetroxide for 1 h. Embryos were washed twice in 0.5USCB, dehydrated in a graded ethanol series, and embedded in EM bed 812 resin (Electron Microscopy Sciences, USA).
Ultrathin (60 nm) longitudinal sections were cut, counter-stained with 2% aqueous uranyl acetate for 20 min then stained with Reynolds lead citrate for 3 min and visualised using a Philips Tecnai 12 transmission electron microscope (FEI, The Netherlands) [18] .
Results and discussion
siRNAs were designed against carboxy-terminal exons 53 and 68 of the zebra¢sh dmd gene, and each was introduced into zebra¢sh embryos by microinjection. The e¡ect of si-RNA-68 was initially assessed by Q-PCR of zebra¢sh dystrophin gene transcripts through the ampli¢cation of the exon targeted by this siRNA. This assessment involved normalisation against two reference genes (L-actin and 18S rRNA). Fig.  1 shows a temporal reduction in the level of the dystrophin family of transcripts, while there was no inhibitory e¡ect of siRNA-68 on the relative expression level of the L-sarcoglycan gene transcript. The protein encoded by this transcript is a member of the DGC complex to which Dp427m binds. Microarray-based studies of Duchenne muscular dystrophy patient muscle have shown that the levels of transcripts encoding the sarcoglycans are not decreased despite reduced levels of Dp427m transcripts in these patients, possibly due to nonsense-mediated decay [19] . As an additional control, siRNA against the transcript of the green £uorescent protein (siRNA-GFP) was also microinjected into zebra¢sh embryos; this si-RNA was used in the studies described by Novina et al. [20] . Q-PCR analysis showed no signi¢cant changes in the level of the dystrophin family of transcripts between injected and uninjected embryos at 12 h post fertilisation (hpf) and 24 hpf (see Supplementary Fig. 1 ).
Confocal microscopy of wholemount zebra¢sh embryos showed that by 24 h of development, dystrophin, L-sarcoglycan and L-dystroglycan are localised to myosepta (Fig. 2) . In contrast, siRNA-68 and siRNA-53 injected embryos showed delayed localisation of dystrophin and L-sarcoglycan (28 hpf), with no apparent delay in terms of L-dystroglycan (24 hpf, Fig. 2) . Interestingly, zebra¢sh treated with a morpholino targeted to the translational start site of Dp427m [21] , and the sapje zebra¢sh mutant that carries a nonsense mutation in exon 4 of the dmd gene [22] exhibit a lack of localisation of dystrophin and members of the sarcoglycan sub-complex of the DGC at zebra¢sh myosepta.
Electron micrographs of zebra¢sh muscle showed disorgan- ised sarcomeres in siRNA-68 and siRNA-53 injected embryos at 36 hpf (Fig. 2) . Light microscopic DIC images of siRNA-53 and siRNA-68 injected embryos showed the delayed development of myotubes, with disruption of the characteristic chevron shape of myosepta yielding U-shaped somites (Fig. 3) . In addition, the larvae of siRNA-68 injected embryos exhibited signi¢cant curvature and reduced motility with an impaired touch response (data not shown). These features are shared to varying extents with those found in zebra¢sh due to morpholino-based translational knockdown of Dp427m [21] and dystroglycan [18] . The sapje mutant is less a¡ected with the detachment of muscle ¢bres from myosepta, which is accompanied by the collapse of sarcomeres [22] . Taken together, our data support the use of siRNAs for gene targeting in the zebra¢sh, albeit in a brief temporal manner, and thus demonstrate the e¡ective use of gene silencing via siRNAs in the last major model organism where this has not been successfully demonstrated previously. The work described here supports the use of siRNAs as a tool to achieve targeted loss of function in a vertebrate model system in which multiple promoters complicate the expression of the targeted gene.
Our conclusion of the speci¢city of gene silencing in zebra¢sh via siRNAs rests on several observations. First, the functional readout of siRNA-68 is at the transcript level, thus negating the possibility of a micro-RNA role for siRNA-68. Secondly, titration experiments have been undertaken to achieve a minimum e¡ective dose of siRNA-68; four-fold higher doses yielded more severe phenotypes (data not shown). Thirdly, siRNA-68 injected embryos provided a similar readout to those injected with siRNA-53 in terms of muscle phenotype. Finally, the data mirror to a large extent the confocal and muscle morphological analyses reported for morpholino-based translational knockdown of the zebra¢sh dystroglycan and dystrophin genes [18, 21] , and the sapje zebra¢sh mutant [22] .
The work described here adheres to the precepts of what constitutes the best controls in gene silencing by RNAi, albeit without the virtue of rescue controls [23] . We have deliberately not used mismatched siRNAs because of their limited usefulness and unanticipated e¡ects [23] . We have assessed speci¢city through Q-PCR analysis that provides evidence supporting a transcriptional e¡ect on the gene we have targeted, with no evidence of non-speci¢c reduction of transcript levels based on the use of three unrelated reference genes. The immunohistochemical and ultrastructural data, and the comparison with morpholino-treated and mutant zebra¢sh reported in the literature, serve to support the transcriptional data. Finally, the lack of any detectable dmd gene transcriptional e¡ects using siRNA-GFP as a negative control underscores the conclusion of siRNA speci¢city.
The outcome of microinjecting siRNAs into zebra¢sh embryos o¡ers similarities to the use of pre-mRNA splice site targeting by morpholinos [24] . The distinction to be drawn here, however, is that the creation of transgenic zebra¢sh lines expressing siRNAs in a tissue-speci¢c or regulated manner could o¡er the means of e¡ecting controlled changes in gene expression in order to ablate as well as to rescue. In this way, siRNA expression cassettes in zebra¢sh have the potential to overcome the limitations of relying on transient unregulated gene targeting, while opening up the possibility of using the zebra¢sh for functional vertebrate gene analysis in a disease context, allowing in vivo targeting of multiple transcripts, whether encoded by one gene or several genes.
